Open Access<p>Effects of Atypical Protein Kinase C Inhibitor (DNDA) on Lung Cancer Proliferation and Migration by PKC-ι/FAK Ubiquitination Through the Cbl-b Pathway</p>
Author(s) -
Raja Reddy Bommareddy,
Rekha Patel,
Tracess Smalley,
Mildred AcevedoDuncan
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s224866
Subject(s) - cancer research , flow cytometry , apoptosis , viability assay , cell growth , lung cancer , western blot , microbiology and biotechnology , protein kinase c , cell , cell cycle , biology , kinase , chemistry , medicine , pathology , biochemistry , gene
The options for treating lung cancers are limited, as diagnosis typically occurs during the late stages of the disease. There is a dire need to develop aPKC (atypical Protein Kinase C) inhibitors due to aPKC overexpression and contributions to lung cancer malignancies. In this study, we investigate the role of atypical PKCs (aPKCs) in cell proliferation and migration in lung cancer cell lines and the effect of the novel aPKC inhibitor DNDA (3,4-amino-2,7 napthalene disulfonic acid).